Evidence map›Paper›PMID 41898634›Full record

ArticleInternational journal of molecular sciences2026

Hydrogen Mitigated Doxorubicin-Induced Liver Injury via Nrf2/HO-1 Pathway Activation.

Meng-Fan Sun, Ji-Xian Song, Miao Tang, Bo-Han Yu, Yao Xiao, Yu-Hui Gao, Zi-Xuan Yao, Ke-Ying An, Zhen-Qun Zhang, Yong-Qing Shen and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Meng-Fan SunHebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.ORCID 0009-0004-2965-104X
Ji-Xian SongHebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Miao TangHebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Bo-Han YuHebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Yao XiaoHebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Yu-Hui GaoHebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Zi-Xuan YaoHebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Ke-Ying AnHebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Zhen-Qun ZhangHebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Yong-Qing ShenSchool of Nursing, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Ya-Shuo ZhaoHebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.ORCID 0000-0002-5793-5574

Funding

Hebei Province medical science research project 20231577Hebei Province medical science research project 2024334
6 · The paper itself

Abstract

Drug-induced liver injury constitutes a major concern within the spectrum of drug-related pathologies. The precise mechanisms underlying doxorubicin (DOX)-induced liver injury remain inadequately elucidated. Hydrogen is known for its selective antioxidant properties and favorable safety profile; however, its protective effects against DOX-induced liver injury have not been fully clarified. In this study, a model of DOX-induced liver injury was established to evaluate hepatic function and pathological alteration, thereby assessing the therapeutic efficacy of hydrogen. Further investigations were conducted to quantify oxidative stress and inflammatory markers to elucidate the potential mechanisms involved. Hydrogen treatment significantly mitigated DOX-induced liver damage and inhibited hepatocyte fibrosis. Hydrogen was found to suppress apoptosis, reduce oxidative stress levels, and ameliorate inflammatory responses in the liver tissue of DOX mice. The protective effect was predominantly facilitated by the modulation of the Nrf2/HO-1 pathway. Importantly, the hepatoprotective effect of hydrogen was negated following the administration of an Nrf2 inhibitor in HepG2 cells. These results suggest that hydrogen may mitigate DOX-induced liver injury by activating the Nrf2/HO-1 signaling pathway, consequently diminishing oxidative stress and inflammatory responses.

Indexed as

Chemical and Drug Induced Liver InjuryDoxorubicinHeme Oxygenase-1HydrogenNF-E2-Related Factor 2Signal TransductionAnimalsApoptosisHep G2 CellsHumansLiverMaleMiceOxidative StressDoxorubicinHeme Oxygenase-1HydrogenNfe2l2 protein, mouseNF-E2-Related Factor 2doxorubicinliver injuryNrf2oxidative stress

Identifiers

PMID41898634
PMCPMC13026534

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.